News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
AstraZeneca PLC (AZN) Seals a $8.5 Billion R&D Cancer Tie-Up With Merck & Co. (MRK) 7/27/2017
AstraZeneca PLC (AZN) Release: TAGRISSO (Osimertinib) Significantly Improves Progression-Free Survival In The Phase III FLAURA Trial For Lung Cancer 7/27/2017
Soligenix (SNGX) Initiates Pivotal Phase III Clinical Trial Of SGX942 (Dusquetide) For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 7/27/2017
Akcea Therapeutics And Ionis Pharma (IONS) Announce Submission Of Marketing Authorization Application For Volanesorsen To The EMA 7/27/2017
Dr. Reddy's Laboratories Ltd. (RDY)’s And CHD Bioscience Announce Global License And Commercialization Agreement For Phase III Clinical Trial Candidate For Mitigation Of Surgical Site Infections 7/27/2017
Amgen (AMGN) Falls After Earnings Update Reveals Embarassingly 'Bare' Pipeline 7/27/2017
Positive Phase III Results Of Genentech (RHHBY)’s Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In The New England Journal of Medicine 7/27/2017
AstraZeneca PLC (AZN) Loses $10 Billion in Value as Long-Awaited MYSTIC Trial Disappoints 7/27/2017
TetraPhase (TTPH) Announces Positive Top-Line Results From Phase III IGNITE4 Clinical Trial In Complicated Intra-Abdominal Infections 7/26/2017
BioCardia Completes Roll-In Cohort In Pivotal Phase III CardiAMP Heart Failure Trial 7/26/2017
Death Count Rises for Patients on Dynavax (DVAX)'s Hep B Vaccine But Overall Rate Was Low, Says the FDA 7/26/2017
Alimera Sciences (ALIM) Announces Real-World Audit Data Supporting The Positive Benefits Of ILUVIEN Treatment 7/26/2017
Eli Lilly (LLY) Shakes Up Cancer R&D Strategy, Seeks New Home for Seven Pipeline Drugs 7/25/2017
2 Tiny Cancer Biotechs That Could Gain Steam by Year-End 7/25/2017
Merck & Co. (MRK) Dealt Another Setback as Its Ace Keytruda Comes Up Short in Head and Neck Cancer Study 7/25/2017
5 Biotechs With $45 Billion Worth of Not-Yet Approved Drugs in the Pipeline 7/25/2017
Massachusetts’ Histogenics Looks to NeoCart for Replacing Knee Cartilage Loss 7/25/2017
BrainStorm Cell Announces Agreement With University of California, Irvine Medical Center To Participate In Phase III Trial Of NurOwn In ALS 7/25/2017
Eisai Inc. (ESALF.PK) Submits Supplemental New Drug Application To FDA For Lenvatinib In First-Line Hepatocellular Carcinoma 7/25/2017
Resverlogix (RVX.TO) Receives Approval Pathway From The FDA As To The Inclusion Of USA Patients In The Phase III BETonMACE Trial 7/25/2017
Neuronix Ltd. Announces The First Group Of Mild To Moderate Alzheimer Patients To Be Successfully Treated By The Neuroad Therapy System In London 7/25/2017
Janssen-Cilag International NV (JNJ) Announces Phase III Pivotal Study Results for Darunavir-Based Complete Treatment Regimen 7/25/2017
The Medicines Company (MDCO) Announces TANGO-2 Trial Of Meropenem-Vaborbactam (Formerly, Carbavance) Stopped Early For Superior Benefit-Risk Compared To Best Available Therapy For CRE 7/25/2017
Merck & Co. (MRK)'s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint Of Non-Inferiority To Efavirenz, Both In Combination With Other Antiretroviral Agents, In Pivotal Phase III Trial For Treatment Of HIV-1 Infection 7/25/2017
Retrophin (RTRX) Commences Patient Dosing In International, Registrational Phase III Trial Of RE-024 In PKAN 7/25/2017
Pacira (PCRX) Announces Topline Phase III Results For EXPAREL As A Single-Dose Nerve Block 7/25/2017
10 Biotechs Tackling Senator John McCain's Form of Aggressive Brain Cancer 7/24/2017
San Diego's Cytori (CYTX) Plunges Scleroderma Med Flunks Phase III Study 7/24/2017
Biohaven (BHVN) Enrolls First Patient In Pivotal Phase III Clinical Trial Of Oral Rimegepant For The Acute Treatment Of Migraine 7/24/2017
Shionogi Announces Positive Top-Line Results For S-033188 Phase III Study (CAPSTONE-1) In Otherwise Healthy Influenza Patients 7/24/2017
Data Put A Dent In Ironwood (IRWD)'s Expansion Plans 7/24/2017
Stealth Biotherapeutics Initiates Phase II/III Study of Elamipretide In Patients With Barth Syndrome 7/24/2017
Tocagen Receives EMA Priority Medicines (PRIME) Designation For Toca 511 In High Grade Glioma 7/24/2017
Pfizer (PFE) Announces Positive Top-Line Results From The Comparative REFLECTIONS B7391003 Study For PF-06439535, A Potential Biosimilar To Avastin 1 (Bevacizumab) 7/24/2017
Gilead (GILD) Boosted By New Late-Stage HIV Data 7/24/2017
Merck & Co. (MRK)'s Once-Daily HIV Drug Works Just As Well As Twice-Daily Formulation 7/24/2017
Uncertainty Hits as Roche (RHHBY) is Dealt Multiple Clinical Trial Setbacks 7/21/2017
Kite Pharma (KITE) Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy 7/21/2017
Lexicon Pharma (LXRX) Collaborator Ipsen (IPN.PA) Receives Positive CHMP Opinion For Xermelo (Telotristat Ethyl) 7/21/2017
SillaJen And Lee's Pharmaceutical Announce Approval By The China CFDA To Commence Phase III Clinical Trial For Oncolytic Immunotherapy, Pexa-Vec, In Liver Cancer 7/21/2017
BrainStorm Cell Awarded $16 Million Non-Dilutive Grant From CIRM In Support Of Phase III Clinical Trial Of NurOwn In ALS 7/21/2017
Amgen (AMGN) Release: FDA Accepts Biologics License Application For Aimovig (erenumab) 7/21/2017
FDA Accepts Biologics License Application For AMG 334 (Erenumab), An Important Regulatory Milestone For Novartis AG (NVS) 7/21/2017
Samsung Bioepis Emerging as a Strong Player in the Autoimmune Space 7/20/2017
U.S. FDA Grants Orphan-Drug Designation To Astellas (ALPMY) For Development Of FLT3 Inhibitor Gilteritinib In Acute Myeloid Leukemia 7/20/2017
Theravance Biopharma (TBPH) AndMylan (MYL) Announce Positive Results From 12-Month Phase III Safety Study Of Revefenacin (TD-4208) In Patients With Chronic Obstructive Pulmonary Disease (COPD) 7/20/2017
Incyte (INCY) Announces First Patient Treated In Phase III Clinical Trial Of Itacitinib For Acute Graft-Versus-Host Disease 7/20/2017
Evolus Announces EMA Acceptance For Review Of The Marketing Authorization Application For DWP-450 Neuromodulator 7/20/2017
Aerie (AERI) Reports Positive Roclatan™ (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Phase III 12-Month Topline Safety Results 7/20/2017
Diffusion Pharma Achieves Drug Production Milestone For Planned Phase III Clinical Trial In Inoperable GBM Brain Cancer 7/20/2017
Trevena (TRVN) To Host 2017 Analyst Day And Announce Results Of ATHENA Open Label Safety Study Of OLINVO 7/20/2017
Kamada (KMDA) Submits Proposed Phase III Protocol To FDA For Inhaled Alpha-1 Antitrypsin For Treatment Of Alpha-1 Antitrypsin Deficiency Disease 7/20/2017
Genentech (RHHBY) R&D Exec Reveals Alzheimer's is Still A Priority 7/19/2017
How Much Money Will These 5 Pharma Companies' Pipelines Generate in 5 Years 7/19/2017
In Alzheimer's, The 'Juggernaut Is Changing Course,' Says TauRx Pharma Chief Exec 7/18/2017
BrainStorm Cell Announces Agreements With Massachusetts General Hospital And California Pacific Medical Center To Participate In Phase III Trial Of NurOwn In ALS 7/18/2017
DelMar Pharma Announces Completion Of First Site Initiation Visit For STAR-3 Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM 7/18/2017
PTC Therapeutics (PTCT) Announces Publication Of Data From ACT DMD In The Lancet 7/18/2017
Paratek Pharma (PRTK)'s Antibiotic Meets All Endpoints in Late-Stage Study 7/18/2017
Abeona Therapeutics Receives Guidance From FDA To Commence Pivotal Phase III For EB-101 Gene Therapy For Patients With Epidermolysis Bullosa 7/18/2017
Leading Retinal Specialists To Highlight pSivida (PSDV)’s Durasert For Treatment Of Posterior Segment Uveitis At Prestigious Ophthalmology Conferences 7/18/2017
Bay Area's Nektar Therapeutics (NKTR) Comes Back With Impressive Opiod Addiction Study Data 7/18/2017
Novartis AG (NVS) Confirms 5 Year Data For First And Only Fully-Human IL-17A Inhibitor Cosentyx Reinforcing Sustained Efficacy And Safety Profile In Psoriasis 7/17/2017
No Relief For Investors As The FDA Keeps Partial Hold On Repros Therapeutics (RPRX)'s Proellex Program 7/17/2017
Spark Therapeutics (ONCE) Announces Publication In The Lancet Of Pivotal Phase III Clinical Trial Data For Investigational Voretigene Neparvovec 7/14/2017
Mallinckrodt (MNK) Phase III Terlipressin Trial Achieves Its Enrollment Target Ahead Of Schedule 7/14/2017
GENFIT (ALGFT) – The NASH Education Programtm Announces The Launch Of The First International NASH Information Day On June 12, 2018: Save The Date! 7/14/2017
Horizon Pharma (HZNP) Announces Four Poster Presentations On PROCYSBI (Cysteamine Bitartrate) Delayed-Release Capsules At Cystinosis Research Network 2017 Family Conference 7/14/2017
Why This Bay Area Pharma Could Win the Hemophilia Race With 'One And Done' Drug 7/13/2017
Amgen (AMGN) Release: Second Phase III Study Shows Kyprolis (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma 7/13/2017
Bio Products Laboratory Presents New Phase III Data Demonstrating Prophylactic Coagadex (Coagulation Factor X, Human) Dosing Prevents Or Reduces Bleeding Episodes In Children With Moderate To Severe Hereditary Factor X Deficiency 7/12/2017
CSL Behring Release: New Data Demonstrate Prophylactic Treatment With IDELVION Reduces Bleed Frequency And Has Potential To Positively Impact Patients With Haemophilia B 7/12/2017
RedHill Biopharma (RDHL) Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn’s Disease 7/12/2017
RedHill Biopharma (RDHL) Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn’s Disease 7/12/2017
Innovate Biopharmaceuticals Submits Orphan Drug Application To FDA For Pediatric Ulcerative Colitis Indication 7/12/2017
Vifor Pharma Announces Three Outcomes Trials In Heart Failure And Iron Deficiency 7/12/2017
Resverlogix (RVX.TO) And Hepalink Start Taiwan/China Trial Of CVD/Diabetes Treatment 7/11/2017
Boehringer Ingelheim Release: Final Phase III Study Results Reinforces Safety And Efficacy Of Praxbind As Reversal Agent For Pradaxa Patients In Emergency Situations 7/11/2017
Boehringer Ingelheim Release: Final Phase III Study Results Confirm Benefit Of Praxbind As Reversal Agent For Pradaxa Patients In Emergency Situations 7/11/2017
ProMetic Life Sci (PFSCF.PK) Announces Positive Long Term Clinical Data On Ryplazym In Plasminogen Congenital Deficiency And Provides Regulatory Update 7/11/2017
Could Alnylam (ALNY) Have An Edge On This Smaller Biotech In Rare Disease? 7/11/2017
Oramed (ORMP) Announces End-Of-Phase II Meeting With FDA To Initiate Phase III Program 7/11/2017
Teva (TEVA) And The Huntington Study Group Announce Publication Of Data For AUSTEDO (Deutetrabenazine) Tablets In Huntington Disease From ARC-HD Study In JAMA Neurology 7/11/2017
Chugai Pharma's Bispecific Antibody "Emicizumab" Global Phase III Data In Patients With Haemophilia A With Inhibitors Published In The New England Journal of Medicine Online 7/10/2017
Resverlogix (RVX.TO) Randomizes First Patient In Taiwan/China Portion Of The Phase III BETonMACE Clinical Trial 7/10/2017
Exelixis (EXEL) And Bristol-Myers Squibb (BMY) Initiate Phase III Trial Of Opdivo In Combination With CABOMETYX Or Opdivo And Yervoy In Combination With CABOMETYX, Versus Sunitinib In Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma 7/10/2017
Genentech (RHHBY) Shows Off Phase III Hemophilia A Data 7/10/2017
Ionis Pharma (IONS) Release: New Data Presented At Peripheral Nerve Society Meeting Further Support Potential Benefit Of Inotersen 7/10/2017
Anthera Pharma (ANTH) Announces RESULT Phase III Clinical Study Of Sollpura Will Be Included In The Cystic Fibrosis Foundation Therapeutics Development Network 7/10/2017
Allergan (AGN) Reports New Data Reinforcing The Effectiveness Of Viberzi (Eluxadoline) To Treat The Symptoms Associated With Irritable Bowel Syndrome With Diarrhea (IBS-D), Abdominal Pain And Diarrhea 7/10/2017
Pluristem Therapeutics (PSTI) Advances Its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation At 40 Active Sites By The End Of 2017 7/10/2017
AC Immune SA Provides Seven Updates On Its Pipeline And Technology At The Alzheimer's Association International Conference 7/10/2017
Prima Biomed (PRR.AX) Announces Approval For The Initiation Of The ‘INSIGHT’ Clinical Trial 7/10/2017
Mark Your Calendars: 7 Biotechs Facing Important Catalysts in July 7/7/2017
Alnylam (ALNY) And Sanofi Genzyme (SNY) Initiate ATLAS Phase III Program With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors 7/7/2017
Puma Biotech (PBYI) Completes Targeted Enrollment In Neratinib Phase III Metastatic Breast Cancer Trial 7/7/2017
Novan To Present Safety And Efficacy Data For SB204 Program In Adolescents At 13th World Congress Of Pediatric Dermatology 7/7/2017
Patient Deaths Prompt the FDA to Suspend Three of Merck & Co. (MRK)'s Keytruda Trials 7/7/2017
Bristol-Myers Squibb (BMY)'s Opdivo Prevails in Phase III Melanoma Trial 7/6/2017
3 Biotechs With Bulging Pipelines That Could Also Become Attractive Takeover Targets 7/6/2017
Bay Area's Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug 7/6/2017
China FDA Approves CTAs For BeyondSpring’s Second Global Plinabulin Registrational Trial For Chemotherapy-Induced Neutropenia Prevention 7/6/2017
Anthera Announces Expansion Of Screening In European Sites In Phase III RESULT Clinical Study Of Sollpura 7/6/2017
Novo Nordisk A/S (NVO) Release: Results From SWITCH Trials For Tresiba Published In The Journal Of The American Medical Association 7/6/2017
Tonix Pharma (TNXP) Announces Conditional Acceptance Of Tonmya As Proposed Brand Name For TNX-102 SL (Cyclobenzaprine HCL Sublingual Tablets) For The Treatment Of PTSD 7/6/2017
Ferring Pharma Announces New Analysis Of Rekovelle Data Relating To Personalised Medicine In Fertility Patients 7/5/2017
Worldwide Clinical Trials Selected By BrainStorm Cell As CRO For Phase III NurOwn Trial In ALS 7/5/2017
Biogen (BIIB)'s SPINRAZA (nusinersen) Receives Notice Of Compliance From Health Canada For The Treatment Of 5q Spinal Muscular Atrophy (SMA) 7/5/2017
Aimmune (AIMT) Enrolls First Patient In ARTEMIS (ARC010) European Phase III Clinical Trial Of AR101 For The Treatment Of Peanut Allergy 7/5/2017
Auris Med (EARS) Completes Enrollment Of Phase III Healos Trial Of Am-111 For The Treatment Of Sudden Deafness 7/5/2017
Bionomics Limited (BNO.AX): A Company With Deals On The Horizon 7/5/2017
Advicenne Receives Orphan Drug Designation From The EU For ADV7103 For The Treatment Of Distal Renal Tubulopathy 7/5/2017
Soleno Therapeutics Announces Successful Completion Of FDA Meeting For DCCR In Prader-Willi Syndrome 7/5/2017
Daiichi Sankyo Jumps On Positive Phase III Pain Data 6/30/2017
Alkermes (ALKS) Slips As Weight Gain Concerns Sully Late-Stage Schizophrenia Data 6/30/2017
FDA Requests More Changes On The Clinical Hold Of CEL-SCI (CVM)'s Head And Neck Cancer Trial 6/30/2017
Merck & Co. (MRK)'s Midas Touch Continues as Heart Drug Succeeds Where Pfizer (PFE), Eli Lilly (LLY) and Roche (RHHBY)'s Failed 6/29/2017
Hutchison China MediTech (Chi-Med) And AstraZeneca PLC (AZN) Initiate SAVOIR, A Global Phase III Trial Of Savolitinib In Papillary Renal Cell Carcinoma 6/29/2017
Myovant (MYOV) Initiates Phase III Clinical Program Of Relugolix In Women With Endometriosis-Associated Pain 6/29/2017
Stealth Biotherapeutics Presents Phase II Data From MMPOWER-2 Continuation Trial Supporting Phase III Development Of Elamipretide In Primary Mitochondrial Myopathy 6/29/2017
ARMO BioSciences Presents Clinical Data On Immunotherapy AM0010 In Advanced Pancreatic Cancer At ESMO World Congress On Gastrointestinal Cancer 2017 6/29/2017
Can Merck & Co. (MRK) And Novartis AG (NVS)'s Surprise Heart Drug Success Translate To Blockbuster Sales? 6/29/2017
Teva (TEVA) Announces Publication Of AIM-TD Study Results In The Lancet Psychiatry For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia 6/29/2017
A Look at the Deaths That Plagued Juno (JUNO) and Kite Pharma (KITE)'s CAR-T Trials 6/29/2017
Why This Washington Pharma Crashed Despite Positive Phase III Migraine Data 6/28/2017
Resverlogix (RVX.TO) Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase III Study Of Apabetalone 6/28/2017
Histogenics Completes Enrollment For Phase III Clinical Trial Of Neocart To Treat Knee Cartilage Damage 6/28/2017
Investors Take Options Cover Ahead Of AstraZeneca PLC (AZN)'s Much-Anticipated Cancer Trial Data 6/28/2017
NovoCure To Present Three Abstracts On Tumor Treating Fields And Pancreatic Cancer At The European Society For Medical Oncology 19th World Congress On Gastrointestinal Cancer 6/28/2017
Alder Biopharma's Migraine Med Hits Goals In Late-Stage Trial 6/27/2017
Genentech (RHHBY)'s Hemophilia Blockbuster Contender Hits Phase III Goals, But Questions Remain 6/27/2017
bluebird bio (BLUE) Announces Topline Interim Clinical Data From Starbeam Study Of Lenti-D Drug Product In Cerebral Adrenoleukodystrophy (CALD) 6/27/2017
Kitov (KTOV) Updates On KIT-302 New Drug Application 6/27/2017
Teva (TEVA), Xenon Pharma's Nerve Pain Med Fails To Meet All Endpoints In Phase III Study 6/27/2017
Strongbridge Biopharma Completes Target Enrollment Of 90 Patients In The Phase III SONICS Study Evaluating RECORLEV (Levoketoconazole) In Endogenous Cushing’s Syndrome 6/27/2017
Will AbbVie (ABBV) Outsmart Biosimilars, And Can Clovis Oncology (CLVS) Win The PARP Race? 6/27/2017
Investors Relieved as Seattle Genetics (SGEN) Pulls Out Win for Phase III Lymphoma Trial 6/27/2017
bluebird bio (BLUE) Touts Impressive Data From Late-Stage Gene Therapy Study 6/26/2017
Bristol-Myers Squibb (BMY) Release: Four-Year Follow-Up With Empliciti (Elotuzumab) Plus Lenalidomide/Dexamethasone (Eld) In Patients With Advanced Multiple Myeloma Shows Long-Term Efficacy In ELOQUENT-2 Trial 6/26/2017
The New England Journal of Medicine Publishes Full Analysis Of Rydapt (Midostaurin) Phase III RATIFY Trial In Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) 6/26/2017
Genentech (RHHBY)’s Emicizumab Showed Positive Results In Phase III Studies (HAVEN 1 And HAVEN 2) In Hemophilia A With Inhibitors 6/26/2017
Chugai Pharma''s Bispecific Antibody Emicizumab To Present Results Of Two Pivotal Phase III Studies At ISTH 6/26/2017
European Hematology Association: Early Metabolic Response Determination By FDG-PET Allows Substantial Reduction Of Chemotherapy And Its Toxicity In Patients With Advanced Stage Hodgkin Lymphoma: The GHSG HD18 Study 6/26/2017
Onconova (ONTX) Presents Rigosertib Data At The 22nd Congress Of The European Hematology Association In Madrid 6/26/2017
Lipocine (LPCN) Announces Submission Of SPA On LPCN 1107, An Oral Alternative For The Prevention Of Preterm Birth 6/26/2017
Mithra Pharmaceuticals Release: Estelle Phase IIb Results On Well-Being And Body Weight Published In Leading Peer-Reviewed Journal 6/26/2017
OSE Immunotherapeutics Announces Temporary Pause Of Patient Accrual While Continuing Treatment For Patients Already Enrolled In Phase III Clinical Trial Of Tedopi In Advanced Lung Cancer 6/26/2017
Amgen (AMGN) Goes on the Defensive When Critics Call Its Pipeline a Dud 6/23/2017
New Data At EAN Show Genentech (RHHBY)’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures Of Disease Progression In Relapsing And Primary Progressive Multiple Sclerosis 6/23/2017
bluebird bio (BLUE) Announces Early Data From Phase III Northstar-2 (HGB-207) Study Of LentiGlobin Drug Product At European Hematology Association Annual Meeting 6/23/2017
Top 3 Biotechs With Potential Blockbusters In The Late-Stage Pipeline 6/22/2017
DelMar Pharma Receives Institutional Review Board Approval For Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM 6/22/2017
Indivior Presents Results From The Phase III Pivotal Study Of RBP-6000 Buprenorphine Monthly Depot For The Treatment Of Opioid Use Disorder 6/22/2017
DURECT (DRRX) Completes Enrollment In PERSIST, Phase III Trial For POSIMIR 6/22/2017
Minerva Neurosciences (NERV) Announces Completion Of Bridging Study To Select Improved Formulation Of MIN-101 For Use In Phase III Trial For The Treatment Of Negative Symptoms In Patients With Schizophrenia 6/22/2017
Alzheon Publishes New Analyses Showing Clinical Benefit Of Tramiprosate In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease; Clinical Effects Suggest Disease Modification And Align With Beta Amyloid Oligomer Formation 6/22/2017
Surprise: Novartis AG (NVS) Heart Drug Wows in Late-Stage Study 6/22/2017
Zogenix (ZGNX) Receives Orphan Drug Designation From FDA For ZX008 In Treatment Of Lennox Gastaut Syndrome 6/22/2017
Advicenne To Present Preliminary Phase III Clinical Data On ADV7103 At The Upcoming European Society Of Pediatric Nephrology’s Annual Meeting 6/22/2017
Money Problems Push SoCal's ImmunoCellular (IMUC) To Suspend Trial, Seek Strategic Alternatives 6/21/2017
Novartis AG (NVS)'s Next-Generation Eye Drug Works With Fewer Injections Than Rivals 6/21/2017
BIO2017: Eli Lilly (LLY) Clinical Development Head Looks to Innovate, Continue Alzheimer’s Research 6/21/2017
Vanda (VNDA): Several Catalysts Coming Up 6/21/2017
Cara Therapeutics (CARA) Reports Continuation Of Phase III Trial Of I.V. CR845 In Postoperative Pain Following Interim Assessment 6/21/2017
Mithra Pharmaceuticals Completes Recruitment For Additional Estelle Safety Study 6/21/2017
Positive Phase III For GlaxoSmithKline (GSK)'s Shingles Vaccine Shingrix With Agenus (AGEN)' QS-21 Stimulon Immune Adjuvant 6/21/2017
GlaxoSmithKline (GSK) Presents Positive Results From Phase III Revaccination Study Of Its Candidate Shingles Vaccine Shingrix At CDC's Advisory Meeting 6/21/2017
Amgen (AMGN) To Present New Data At 22nd Congress Of The European Hematology Association 6/21/2017
More Deaths Lead Seattle Genetics (SGEN) to Discontinue Phase III Leukemia Study 6/21/2017
Clovis Oncology (CLVS) Stock Soars as Ovarian Cancer Trial Dazzles 6/21/2017
Inovio Pharma (INO) CEO Forging Multiple Deals, Expanding Pipeline and Adding 100 New Jobs 6/20/2017
How Upcoming Mystic Data Will Be AstraZeneca PLC (AZN) CEO's Biggest Test 6/20/2017
AVEO Oncology (AVEO) Announces Pivotal Phase III TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma Reaches Enrollment Target 6/20/2017
Immune Pharma Announces Initiation Of Enrollment In Clinical Trial With Ceplene/ Low-Dose IL-2 In Chronic Myelomonocytic Leukemia (CMML) 6/20/2017
Helsinn Group Announces Upcoming Presentation Of Phase III Data In NEPA (Netupitant/Palonestron) At MASCC/ISOO Congress In Washington DC 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
Lipocine (LPCN) Validates “No Titration” Dosing Regimen With Positive Topline Efficacy Results For LPCN 1021, Oral Testosterone Candidate 6/20/2017
New Data Reveals This New York Biotech's Pipeline Could be a Game Changer 6/19/2017
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines 6/19/2017
ASIT Biotech Discloses Comments From The Paul Ehrlich Institute And Presents Detailed Results On The Phase III Clinical Study Of Gp-ASIT + At EAACI 2017 6/19/2017
VBI Vaccines Reports Positive Outcome From Phase III Pre-IND Discussions With The FDA For Hepatitis B Vaccine, Sci-B-Vac 6/19/2017
RedHill Biopharma (RDHL) To Host Conference Call On Successful Phase III Top-Line Results With BEKINDA For Acute Gastroenteritis 6/19/2017
Janssen-Cilag AG Release: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit With Single Agent Imbruvica (Ibrutinib) Vs Temsirolimus At First Relapse In Mantle Cell Lymphoma 6/19/2017
Why Drug Giants Like Merck & Co. (MRK) and AstraZeneca PLC (AZN) Scientists are Looking in the Toilet for New Cancer Treatments 6/16/2017
Why This Overlooked New Jersey Biotech Could be an Orphan Underdog 6/16/2017
EULAR 2017: Eli Lilly (LLY)'s Taltz (ixekizumab) Demonstrated No Progression Or Minimal Progression Of Radiographic Disease In Patients With Psoriatic Arthritis Through 52 Weeks 6/16/2017
Eli Lilly (LLY) Release: New Safety And Long-Term Efficacy Data From Baricitinib Clinical Trials In Patients With Moderate-To-Severe Rheumatoid Arthritis Presented At EULAR 2017 6/16/2017
DelMar Pharma Presents Poster Of Clinical Research With VAL-083 In Patients With Chemo-Resistant Glioblastoma ("GBM") At SNO's Pediatric Neuro-Oncology Basic And Translational Research Conference 6/16/2017
TG Therapeutics (TGTX) Recaps Positive Data From The Phase III GENUINE Trial And Data From The Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 14th International Conference On Malignant Lymphoma 6/16/2017
Xeris Pharma Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program 6/16/2017
Bavarian Nordic (BAVA.CO) Provides Update On Anticipated Timing Of PROSPECT Study 6/16/2017
How Your Daily Cup Of Coffee Could Be Saving Your Liver, Journal of Hepatology Reveals 6/15/2017
Opko Health (OPK) Provides Update To Topline Data Of Phase III Clinical Study Of Hgh-CTP In Growth Hormone Deficient Adults 6/15/2017
LEO Pharma Starts Phase III Clinical Study For Tralokinumab In Atopic Dermatitis 6/15/2017
RedHill Biopharma (RDHL) Announces Confirmatory Phase III Study Initiated With RHB-105 (TALICIA) For H. Pylori Infection 6/15/2017
Braeburn Pharma And Camurus Announce Presentations Of Pivotal Clinical Study Data Of Long-Acting Buprenorphine 6/15/2017
EULAR 2017: Eli Lilly (LLY)'s Taltz (Ixekizumab) Demonstrated Significant Improvements In Disease Signs And Symptoms At 24 Weeks Among Patients With Active Psoriatic Arthritis Who Had Prior Inadequate Response Or Intolerance To TNF Inhibitors 6/15/2017
Sirnaomics Advances Leading siRNA Therapeutic Candidate, STP705, For Treatment Of Liver Fibrosis 6/15/2017
RedHill Biopharma (RDHL) Announces Successful Phase III Top-Line Results With BEKINDA For Acute Gastroenteritis 6/15/2017
Achelios Therapeutics Concludes Successful Type C Meeting With FDA Regarding Its Lead Product, TOPOFEN, For Prevention And Treatment Of Migraine 6/14/2017



//-->